Tests new drug combinations on leukemia cells from patients in mice
Studies donated leukemia cells from adults with acute myeloid leukemia, grown in special mice.
Plain-language title generated from the registry record
Registry title: Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
Key facts
- Where
- Canberra, Sydney, and Westmead, AustraliaSee the 4 sites
Where in Australia
- Canberra Health ServicesCanberra, AustraliaTaking people
- Prince of Wales HospitalSydney, AustraliaTaking people
- Royal North Shore HospitalSydney, AustraliaNot yet recruiting
- Westmead HospitalWestmead, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Clinical Hub for Interventional Research (CHOIR)
- Trial code
- NCT06782971
- Record updated
- 8 December 2025
- Original description
The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are:Read full original descriptionShow less
COSMOS-Avatar: Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are:
* Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived?
Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.
Inclusion: Age 18 years and above; Patients with suspicion of AML requiring screening procedures; Documented diagnosis of AML by WHO Classification and/or International Consensus Classification; Regardless of the number and type of prior lines of therapy or eligibility for allogeneic stem cell transplantation; All AML subtypes are eligible; Concurrent participation in clinical trials is allowed; Documented myeloblast percentage ≥20% in the bone marrow or peripheral blood within 12 weeks of C1D1 confirmed by bone marrow aspirate or peripheral blood smear; Planned to commence venetoclax and azacitidine therapy; Provision of written informed consent prior to any study-related assessments or procedures being carried out.
Exclusion: Presence of any condition that, by assessment of the Investigator, would compromise the safety of the patient if they participated, the quality of trial data, or their adherence to the study-specified procedures.